X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims to create a time-release ketamine implant, SP-26, which blocks the activity of the N-methyl-D-aspartate receptor (NMDAR), to treat fibromyalgia and other chronic pain conditions.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Musculoskeletal Product Name: SP-26
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zylo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 23, 2023
Details:
The agreement aims to study and develop a dosage and time-release ketamine implant for the treatment of fibromyalgia, alongside development of SP-26, company's novel time-release topical formulation of ketamine.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 14, 2023
Details:
In the most recent phase of this ongoing animal study, tests were conducted to evaluate the disease-suppressive effects of an SPU-21 (psilocybin) peptide-guided anti-arthritis drug versus the drug alone.
Lead Product(s): Psilocybine,Dexamethasone
Therapeutic Area: Immunology Product Name: SPU- 21
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Maryland
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2022
Details:
Under the agreement, Silo has been granted an option to license psychedelics as a therapeutic currently under development, for Alzheimer’s disease.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Columbia University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 27, 2021
Details:
The joint venture will initially explore the clinical development of ketamine using ZTI’s Z-pod technology, but also provides for Silo Pharma to obtain an exclusive option for the clinical development of psilocybin using ZTI’s Z-pod technology as well.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Zylo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 28, 2021
Details:
The patent applications pertain to Silo Pharma’s novel and proprietary central nervous system (CNS) homing peptides for use in the therapeutic treatment of pain from neuroinflammation in cancer patients.
Lead Product(s): Psilocybine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
